Trade UNCY stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Unicycive Therapeutics, Inc. (UNCY) is trading at US$4.89, up 2.41% today as of Sep 22, 13:39 EDT. The company has a market capitalisation of US$156.83M. Over the past 52 weeks, UNCY has traded between US$3.71 and US$8.74. On Syfe you can trade UNCY with $0 commission and add it to your watchlist.
| Previous close | US$4.77 |
|---|---|
| Market cap | US$156.83M |
| P/E ratio | 5.03 |
| 52-week range | US$3.71 – US$8.74 |
| Volume | 446.31K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
Year: 2021
B. Riley Adjusts Price Target on Unicycive Therapeutics to $20 From $22, Maintains Buy Rating
Aug 13, 12:21 PM · MT Newswires
Sector Update: Healthcare Stocks Softer Late Afternoon
Jun 30, 7:41 PM · MT Newswires
Top Midday Decliners
Jun 30, 6:41 PM · MT Newswires
Unicycive Therapeutics Gets FDA's Complete Response Letter for Resubmitted Oxylanthanum Carbonate NDA
Jun 30, 12:25 PM · MT Newswires
Top Premarket Decliners
Jun 30, 11:35 AM · MT Newswires
Unicycive Therapeutics, Inc. (UNCY) stock is trading at US$4.89, +2.41% from the previous close of US$4.77.
The market cap for Unicycive Therapeutics, Inc. (UNCY) stock is approximately US$156.83M.
The price-to-earnings ratio for Unicycive Therapeutics, Inc. (UNCY) is 5.03, based on the latest reported earnings.
The 52-week high for Unicycive Therapeutics, Inc. (UNCY) stock is US$8.74.
The 52-week low for Unicycive Therapeutics, Inc. (UNCY) stock is US$3.71.
Unicycive Therapeutics, Inc. (UNCY) does not currently pay a dividend.
Stay on top of UNCY
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
